1d
Medical Device Network on MSNMedtronic reports late-breaking data from TAVR system trial for aortic stenosisMedtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...
Medtronic says its Evolut TAVR shows strong valve performance and durable outcomes at 5 years in low-risk aortic stenosis ...
Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...
Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.
Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...
Medtronic Evolut TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients: Galway, Ireland Tuesday, April 1 ...
Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...
Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.
Medtronic (MDT) announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut ...
Medtronic (NYSE: MDT) stock was a fairly hot item as the trading week kicked off, with investors pushing the shares up by ...
Medtronic (NYSE:MDT) recently saw a substantial price movement, climbing 10% over the last quarter. This period was marked by ...
Among patients with severe aortic stenosis at low surgical risk, transcatheter aortic valve replacement and surgery conferred ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results